BAUSCH HEALTH (BHC)
$5.49
0.16 (2.91%)
BHC Stock Quote Delayed 30 Minutes
16 Stocks to Buy Before They Turn It Around
GE stock is just one of the many turnaround stocks in the market. These 16 equities all could be stocks to buy - if execution improves.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$5.67
Market Cap
2.09B
PE Ratio
-43.92
EPS
-0.125
Volume (Avg. Vol.)
3.17M
Day's Range
$5.10 - $5.57
52-Week Range
$3.96 - $10.48
Dividend & Yield
N/A (N/A)
BHC Stock Predictions, Articles, and BAUSCH HEALTH News
Can Sprout Pharma’s Latest Revival Really Boost VRX Stock?
Sprout Pharma is about to revive the libido pill, Addyi. With the same leadership but autonomy from Valeant Pharma, Sprout could turn the drug into a success story.
Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play
Teva Pharmaceuticals is quietly moving higher on the stock market for good reason: worries over pricing and the impact of competition in generics is getting clearer. Teva stock is a great long-term bet.
Valeant Pharmaceuticals Intl Inc Has New Name But Same Problems
Valeant has put its scandals into the past and will change its name to Bausch, but it still has debt worth three times annual sales.
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
Wednesday’s Vital Data: Valeant Pharmaceuticals Intl Inc (VRX), Walt Disney Co (DIS) and Citigroup Inc (C)
Valeant (VRX) and Disney (DIS) options volume jumped on earnings while Citigroup (C) spikes as ValueAct takes a $1.2 billion stake.
4 Top Stock Trades for Wednesday Morning
Stocks had trouble finding direction on Tuesday, partly due to the Iran deal and the U.S. However, we're still looking for top stock trades going forward.
Valeant Pharmatceutical’s Debt Won’t Be Fooled by a Name Change
Valeant will soon become Bausch Health, but it will retain the debt it incurred on the way to its 2015 scandal.
How Valeant Pharmaceuticals Intl Inc Can Give You a 750% Return
Improving bottom-lines off and on the price chart in Valeant stock build the case for an out-of-the-money bull call spread. Here's what you should do with VRX.
Intangibles Hold the Key to Valeant Pharmaceuticals Intl Inc Stock
Valeant stock plunged on lower guidance, but Valeant is paying down debt and releasing new products which could help VRX recover.
Valeant Pharmaceuticals Intl Inc Stock Tumbles on Q4 Revenue Miss
Valeant Pharmaceuticals (VRX) stock took a hit today following the release of its earnings report for the fourth quarter of 2017.
Valeant Pharmaceuticals International (VRX) a Buy on Solid Quant Score
Valeant Pharmaceuticals International Inc (NYSE:VRX) is one of the 657 companies in the GICS Health Technology sector, and a constituent of the 96 company Pharmaceuticals: Other GICS industry group within this sector. VRX's market value is $7.5 billion which places it in the top 10% of its industry group. Portfolio Grader's current ranking for VRX puts it 20 among the 96 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 160 among the 657 companies in the sector, and number 1,087 in the nearly 5,000 company Portfolio Grader universe.
Valeant Pharmaceuticals Intl Inc Stock Rides High as More Good News Awaits
VRX stock has soared in recent months as investors expect Valeant to continue improving its business in 2018.
Is Valeant Pharmaceuticals Intl Inc a Buy? 3 Pros, 3 Cons
Under CEO Joseph Papa, Valeant has reduced its debt by over $6 billion. But legal liabilities for the company remain. Is VRX stock a buy?
Valeant Pharmaceuticals Intl Inc Stock Is Worth the Risk
Valeant stock looks poised for recovery as a new CEO is turning VRX around by paying off debts and creating new markets for Valeant products.
Earnings Momentum Keep Valeant Pharmaceuticals International (VRX) a Buy
Valeant Pharmaceuticals International Inc (NYSE:VRX) ranks in the top 25% of its industry group, Pharmaceuticals, and in the top 25% of its sector group, Health Care, with a market value of $7.2 billion. From an investment attractiveness viewpoint, VRX is ranked in the top quartile of the sector with a ranking of 148 among the 779 companies in the sector; the stock's Portfolio Grader ranking places it 21 among the 134 companies in this industry group, giving it a well above-average position and number 871 in the 5000 company Portfolio Grader company universe.
